Titre : Autoanticorps

Autoanticorps : Questions médicales fréquentes

Termes MeSH sélectionnés :

Cellular Reprogramming
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Autoanticorps : Questions médicales les plus fréquentes", "headline": "Autoanticorps : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Autoanticorps : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-22", "dateModified": "2025-02-16", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Autoanticorps" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Anticorps", "url": "https://questionsmedicales.fr/mesh/D000906", "about": { "@type": "MedicalCondition", "name": "Anticorps", "code": { "@type": "MedicalCode", "code": "D000906", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Anticorps anti-protéines citrullinées", "alternateName": "Anti-Citrullinated Protein Antibodies", "url": "https://questionsmedicales.fr/mesh/D000075422", "about": { "@type": "MedicalCondition", "name": "Anticorps anti-protéines citrullinées", "code": { "@type": "MedicalCode", "code": "D000075422", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.095" } } }, { "@type": "MedicalWebPage", "name": "Anticorps antinucléaires", "alternateName": "Antibodies, Antinuclear", "url": "https://questionsmedicales.fr/mesh/D000974", "about": { "@type": "MedicalCondition", "name": "Anticorps antinucléaires", "code": { "@type": "MedicalCode", "code": "D000974", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.204" } } }, { "@type": "MedicalWebPage", "name": "Anticorps antiphospholipides", "alternateName": "Antibodies, Antiphospholipid", "url": "https://questionsmedicales.fr/mesh/D017152", "about": { "@type": "MedicalCondition", "name": "Anticorps antiphospholipides", "code": { "@type": "MedicalCode", "code": "D017152", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.210" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Anticorps anticardiolipines", "alternateName": "Antibodies, Anticardiolipin", "url": "https://questionsmedicales.fr/mesh/D017153", "about": { "@type": "MedicalCondition", "name": "Anticorps anticardiolipines", "code": { "@type": "MedicalCode", "code": "D017153", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.210.100" } } } ] }, { "@type": "MedicalWebPage", "name": "Facteur néphritique C3", "alternateName": "Complement C3 Nephritic Factor", "url": "https://questionsmedicales.fr/mesh/D003178", "about": { "@type": "MedicalCondition", "name": "Facteur néphritique C3", "code": { "@type": "MedicalCode", "code": "D003178", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.300" } } }, { "@type": "MedicalWebPage", "name": "Immunoconglutinines", "alternateName": "Immunoconglutinins", "url": "https://questionsmedicales.fr/mesh/D037561", "about": { "@type": "MedicalCondition", "name": "Immunoconglutinines", "code": { "@type": "MedicalCode", "code": "D037561", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.390" } } }, { "@type": "MedicalWebPage", "name": "Immunoglobulines thyréostimulantes", "alternateName": "Immunoglobulins, Thyroid-Stimulating", "url": "https://questionsmedicales.fr/mesh/D018828", "about": { "@type": "MedicalCondition", "name": "Immunoglobulines thyréostimulantes", "code": { "@type": "MedicalCode", "code": "D018828", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.480" } } }, { "@type": "MedicalWebPage", "name": "Facteur rhumatoïde", "alternateName": "Rheumatoid Factor", "url": "https://questionsmedicales.fr/mesh/D012217", "about": { "@type": "MedicalCondition", "name": "Facteur rhumatoïde", "code": { "@type": "MedicalCode", "code": "D012217", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.732" } } } ], "about": { "@type": "MedicalCondition", "name": "Autoanticorps", "alternateName": "Autoantibodies", "code": { "@type": "MedicalCode", "code": "D001323", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Iago Pinal-Fernandez", "url": "https://questionsmedicales.fr/author/Iago%20Pinal-Fernandez", "affiliation": { "@type": "Organization", "name": "Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA andrew.mammen@nih.gov iago.pinalfernandez@nih.gov." } }, { "@type": "Person", "name": "Katherine Pak", "url": "https://questionsmedicales.fr/author/Katherine%20Pak", "affiliation": { "@type": "Organization", "name": "Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA." } }, { "@type": "Person", "name": "Sarah L Tansley", "url": "https://questionsmedicales.fr/author/Sarah%20L%20Tansley", "affiliation": { "@type": "Organization", "name": "Department of Pharmacy and pharmacology, University of Bath, Bath, UK." } }, { "@type": "Person", "name": "Gunnar Houen", "url": "https://questionsmedicales.fr/author/Gunnar%20Houen", "affiliation": { "@type": "Organization", "name": "Department of Autoimmunology, Statens Serum Institut, Copenhagen, Denmark. gh@ssi.dk." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Veillonella parvula promotes the proliferation of lung adenocarcinoma through the nucleotide oligomerization domain 2/cellular communication network factor 4/nuclear factor kappa B pathway.", "datePublished": "2023-07-14", "url": "https://questionsmedicales.fr/article/37452162", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s12672-023-00748-6" } }, { "@type": "ScholarlyArticle", "name": "Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV - a prospective observational cohort study.", "datePublished": "2023-06-16", "url": "https://questionsmedicales.fr/article/37331161", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ebiom.2023.104661" } }, { "@type": "ScholarlyArticle", "name": "Discovery of New 2-Phenylamino-3-acyl-1,4-naphthoquinones as Inhibitors of Cancer Cells Proliferation: Searching for Intra-Cellular Targets Playing a Role in Cancer Cells Survival.", "datePublished": "2023-05-24", "url": "https://questionsmedicales.fr/article/37298798", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/molecules28114323" } }, { "@type": "ScholarlyArticle", "name": "New Platform for Label-Free, Proximal Cellular Pharmacodynamic Assays: Identification of Glutaminase Inhibitors Using Infrared Matrix-Assisted Laser Desorption Electrospray Ionization Mass Spectrometry.", "datePublished": "2023-04-12", "url": "https://questionsmedicales.fr/article/37043689", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1021/acschembio.3c00087" } }, { "@type": "ScholarlyArticle", "name": "Longitudinal Analysis of Humoral and Cellular Immune Response Following SARS-CoV-2 Vaccination Supports Utilizing Point-Of-Care Tests to Enhance COVID-19 Booster Uptake.", "datePublished": "2023-04-04", "url": "https://questionsmedicales.fr/article/37066219", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1101/2023.04.03.23287498" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Globulines", "item": "https://questionsmedicales.fr/mesh/D005916" }, { "@type": "ListItem", "position": 5, "name": "Sérum-globulines", "item": "https://questionsmedicales.fr/mesh/D012712" }, { "@type": "ListItem", "position": 6, "name": "Immunoglobulines", "item": "https://questionsmedicales.fr/mesh/D007136" }, { "@type": "ListItem", "position": 7, "name": "Anticorps", "item": "https://questionsmedicales.fr/mesh/D000906" }, { "@type": "ListItem", "position": 8, "name": "Autoanticorps", "item": "https://questionsmedicales.fr/mesh/D001323" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Autoanticorps - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Autoanticorps", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-08", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Autoanticorps", "description": "Comment détecte-t-on les autoanticorps ?\nQuels tests sont utilisés pour les autoanticorps ?\nLes autoanticorps sont-ils toujours présents dans les maladies auto-immunes ?\nPeut-on avoir des autoanticorps sans symptômes ?\nQuel rôle jouent les autoanticorps dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D001323?mesh_terms=Cellular+Reprogramming&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Autoanticorps", "description": "Quels symptômes sont associés aux autoanticorps ?\nLes autoanticorps causent-ils des douleurs articulaires ?\nPeut-on avoir des symptômes neurologiques avec des autoanticorps ?\nLes éruptions cutanées sont-elles liées aux autoanticorps ?\nLes autoanticorps peuvent-ils affecter les organes internes ?", "url": "https://questionsmedicales.fr/mesh/D001323?mesh_terms=Cellular+Reprogramming&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Autoanticorps", "description": "Peut-on prévenir la production d'autoanticorps ?\nLes vaccinations influencent-elles les autoanticorps ?\nLe stress peut-il augmenter les autoanticorps ?\nL'alimentation joue-t-elle un rôle dans la prévention ?\nLes examens médicaux réguliers aident-ils à la prévention ?", "url": "https://questionsmedicales.fr/mesh/D001323?mesh_terms=Cellular+Reprogramming&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Autoanticorps", "description": "Comment traite-t-on les maladies liées aux autoanticorps ?\nLes traitements sont-ils les mêmes pour tous les autoanticorps ?\nLes thérapies biologiques sont-elles efficaces contre les autoanticorps ?\nPeut-on guérir des maladies causées par des autoanticorps ?\nLes changements de mode de vie aident-ils à gérer les autoanticorps ?", "url": "https://questionsmedicales.fr/mesh/D001323?mesh_terms=Cellular+Reprogramming&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Autoanticorps", "description": "Quelles complications peuvent survenir avec des autoanticorps ?\nLes autoanticorps peuvent-ils causer des maladies cardiovasculaires ?\nLes complications sont-elles réversibles ?\nLes infections sont-elles plus fréquentes avec des autoanticorps ?\nLes complications neurologiques sont-elles possibles ?", "url": "https://questionsmedicales.fr/mesh/D001323?mesh_terms=Cellular+Reprogramming&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Autoanticorps", "description": "Quels sont les facteurs de risque pour les autoanticorps ?\nL'âge influence-t-il la production d'autoanticorps ?\nLes facteurs environnementaux jouent-ils un rôle ?\nLe tabagisme est-il un facteur de risque ?\nLes déséquilibres hormonaux affectent-ils les autoanticorps ?", "url": "https://questionsmedicales.fr/mesh/D001323?mesh_terms=Cellular+Reprogramming&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment détecte-t-on les autoanticorps ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Les autoanticorps sont détectés par des tests sanguins spécifiques, comme l'ELISA." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour les autoanticorps ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests courants incluent le dosage des anticorps antinucléaires (ANA) et des anticorps spécifiques." } }, { "@type": "Question", "name": "Les autoanticorps sont-ils toujours présents dans les maladies auto-immunes ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, leur présence peut varier selon la maladie et le stade de la maladie." } }, { "@type": "Question", "name": "Peut-on avoir des autoanticorps sans symptômes ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines personnes peuvent avoir des autoanticorps sans présenter de symptômes cliniques." } }, { "@type": "Question", "name": "Quel rôle jouent les autoanticorps dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Ils aident à confirmer le diagnostic de maladies auto-immunes et à évaluer leur activité." } }, { "@type": "Question", "name": "Quels symptômes sont associés aux autoanticorps ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes varient, mais peuvent inclure fatigue, douleurs articulaires et éruptions cutanées." } }, { "@type": "Question", "name": "Les autoanticorps causent-ils des douleurs articulaires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent provoquer des douleurs articulaires dans des maladies comme la polyarthrite rhumatoïde." } }, { "@type": "Question", "name": "Peut-on avoir des symptômes neurologiques avec des autoanticorps ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains autoanticorps sont associés à des troubles neurologiques comme la sclérose en plaques." } }, { "@type": "Question", "name": "Les éruptions cutanées sont-elles liées aux autoanticorps ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des éruptions cutanées peuvent survenir dans des maladies comme le lupus érythémateux systémique." } }, { "@type": "Question", "name": "Les autoanticorps peuvent-ils affecter les organes internes ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent endommager des organes comme les reins, le cœur ou les poumons dans certaines maladies." } }, { "@type": "Question", "name": "Peut-on prévenir la production d'autoanticorps ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de méthode garantie, mais un mode de vie sain peut réduire les risques." } }, { "@type": "Question", "name": "Les vaccinations influencent-elles les autoanticorps ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Certaines vaccinations peuvent déclencher des autoanticorps, mais les bénéfices l'emportent souvent." } }, { "@type": "Question", "name": "Le stress peut-il augmenter les autoanticorps ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut exacerber les maladies auto-immunes et augmenter les autoanticorps." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle dans la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en antioxydants et en oméga-3 peut aider à réduire l'inflammation." } }, { "@type": "Question", "name": "Les examens médicaux réguliers aident-ils à la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des examens réguliers peuvent aider à détecter précocement les maladies auto-immunes." } }, { "@type": "Question", "name": "Comment traite-t-on les maladies liées aux autoanticorps ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement inclut des immunosuppresseurs, des anti-inflammatoires et des corticostéroïdes." } }, { "@type": "Question", "name": "Les traitements sont-ils les mêmes pour tous les autoanticorps ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Non, le traitement dépend du type de maladie auto-immune et des autoanticorps présents." } }, { "@type": "Question", "name": "Les thérapies biologiques sont-elles efficaces contre les autoanticorps ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines thérapies biologiques ciblent spécifiquement les mécanismes des maladies auto-immunes." } }, { "@type": "Question", "name": "Peut-on guérir des maladies causées par des autoanticorps ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de guérison, mais les traitements peuvent contrôler les symptômes et la progression." } }, { "@type": "Question", "name": "Les changements de mode de vie aident-ils à gérer les autoanticorps ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation équilibrée, l'exercice et la gestion du stress peuvent aider à la gestion." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des autoanticorps ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des dommages aux organes, des infections et des troubles auto-immuns." } }, { "@type": "Question", "name": "Les autoanticorps peuvent-ils causer des maladies cardiovasculaires ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains autoanticorps sont associés à un risque accru de maladies cardiovasculaires." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent causer des dommages permanents." } }, { "@type": "Question", "name": "Les infections sont-elles plus fréquentes avec des autoanticorps ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients avec des maladies auto-immunes ont un risque accru d'infections." } }, { "@type": "Question", "name": "Les complications neurologiques sont-elles possibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications neurologiques peuvent survenir, comme des troubles cognitifs ou des crises." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les autoanticorps ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, le sexe féminin et certaines infections." } }, { "@type": "Question", "name": "L'âge influence-t-il la production d'autoanticorps ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la production d'autoanticorps augmente souvent avec l'âge, surtout chez les femmes." } }, { "@type": "Question", "name": "Les facteurs environnementaux jouent-ils un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des toxines ou à des infections peut déclencher la production d'autoanticorps." } }, { "@type": "Question", "name": "Le tabagisme est-il un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme est associé à un risque accru de maladies auto-immunes et d'autoanticorps." } }, { "@type": "Question", "name": "Les déséquilibres hormonaux affectent-ils les autoanticorps ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les déséquilibres hormonaux, notamment chez les femmes, peuvent influencer la production d'autoanticorps." } } ] } ] }

Sources (10000 au total)

Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV - a prospective observational cohort study.

We investigated long-term durability of humoral and cellular immune responses to third dose of BNT162b2 in people with HIV (PWH) and controls.... In 378 PWH with undetectable viral replication and 224 matched controls vaccinated with three doses of BNT162b2, we measured IgG-antibodies against the receptor binding domain of SARS-CoV-2 spike prot... Before the third dose the concentration of SARS-CoV-2 antibodies was lower in PWH than in controls (unadjusted geometric mean ratio (GMR): 0.68 (95% CI: 0.54-0.86, p = 0.002). We observed no differenc... We found no differences in antibody concentrations or cellular response between PWH and controls up to eleven months after third dose of BNT162b2. Our findings indicate that PWH with undetectable vira... This work was funded by the Novo Nordisk Foundation (NFF205A0063505, NNF20SA0064201), the Carlsberg Foundation (CF20-476 0045), the Svend Andersen Research Foundation (SARF2021), and Bio- and Genome B...

Discovery of New 2-Phenylamino-3-acyl-1,4-naphthoquinones as Inhibitors of Cancer Cells Proliferation: Searching for Intra-Cellular Targets Playing a Role in Cancer Cells Survival.

A series of 2-phenylamino-3-acyl-1,4-naphtoquinones were evaluated regarding their in vitro antiproliferative activities using DU-145, MCF-7 and T24 cancer cells. Such activities were discussed in ter...

New Platform for Label-Free, Proximal Cellular Pharmacodynamic Assays: Identification of Glutaminase Inhibitors Using Infrared Matrix-Assisted Laser Desorption Electrospray Ionization Mass Spectrometry.

Cellular pharmacodynamic assays are crucial aspects of lead optimization programs in drug discovery. These assays are sometimes difficult to develop, oftentimes distal from the target and frequently l...

Longitudinal Analysis of Humoral and Cellular Immune Response Following SARS-CoV-2 Vaccination Supports Utilizing Point-Of-Care Tests to Enhance COVID-19 Booster Uptake.

Individuals with weaker neutralizing responses show reduced protection with SARS-CoV-2 variants. Booster vaccines are recommended for vaccinated individuals, but the uptake is low. We present the feas... SARS-CoV-2 point-of-care antibody tests are valuable and easy-to-access tools to inform inadequate humoral immunity and to support informed decision-making regarding the current and future booster vac...

Hybridization of triphenylamine to BODIPY dyes at the 3,5,8-positions: A facile strategy to construct near infra-red aggregation-induced emission luminogens with intramolecular charge transfer for cellular imaging.

A series of five BODIPY derivatives with triarylamine (TPA) moieties on their 3-, 5-, or 8-positions were reported, which showed wide-range fluorescence emissions across red and near infrared regions ...

Viral infection in hematopoietic stem cell transplantation: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review on the role of cellular therapy in prevention and treatment.

Despite recent advances in the field of HSCT, viral infections remain a frequent causeof morbidity and mortality among HSCT recipients. Adoptive transfer of viral specific T cells has been successfull...